China-based nucleic acid drug specialist Suzhou HealiRNA has reportedly raised over RMB 100 million (USD 14.35 million) in a pre-Series A financing round. The round was led by MING Bioventures, with additional investments from Shunwei Capital, China-Singapore Suzhou Industrial Park Private Equity Management Co., Ltd, and existing investor Sequoia Capital China.
Use of Funds
The proceeds will be used to support clinical studies for the mRNA product pipeline, expand the research and development (R&D) team, construct the siRNA platform, and expand the Phase II R&D center. The company expects to advance 1-2 products into the clinical stage this year.
Company Overview and Platforms
Founded in 2021, HealiRNA offers comprehensive nucleic acid drug R&D and manufacturing platforms. These include an innovative nucleic acid delivery carrier development platform, a superfluids production platform, and a high-throughput, intelligent mRNA design and synthesis platform. These platforms position HealiRNA at the forefront of nucleic acid drug innovation.
Significance of the Funding
This pre-Series A funding round provides HealiRNA with the necessary resources to accelerate its development and expand its capabilities in the nucleic acid drug market. By investing in R&D and infrastructure, the company aims to bring innovative and effective treatments to patients globally.-Fineline Info & Tech